Hester Biosciences' Q4 FY 2025-26 Quarterly Results

Result Summary

• Hester Biosciences Ltd reported a 24.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 29.5%.
• Its expenses for the quarter were up by 16.6% QoQ and 5.9% YoY.
• The net profit increased 77.8% QoQ and increased 974.0% YoY.
• The earnings per share (EPS) of Hester Biosciences Ltd stood at 19.45 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Hester Biosciences Ltd is a company that operates within the pharmaceutical industry, primarily focusing on the production and distribution of vaccines and other related products for veterinary and human health. The company is headquartered in India and has established itself as a key player in the biotechnology sector. It is known for its innovative approach to vaccine development and has a diverse product portfolio that serves both domestic and international markets. As of the latest updates, Hester Biosciences has been involved in various strategic initiatives to expand its market reach and enhance product offerings. However, specific details on recent major developments are not available in the current dataset.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), Hester Biosciences Ltd reported a total income of ₹97.08 crores. This represents a significant increase of 24.3% from the previous quarter (Q3FY26), where total income was ₹78.08 crores. On a year-over-year basis, the total income grew by 29.5% compared to ₹74.98 crores in the fourth quarter of the fiscal year 2025 (Q4FY25). The notable growth in revenue over both periods indicates a robust performance in terms of income generation, reflecting the company's capacity to enhance its sales and possibly expand its market presence during this timeframe.

Profitability

The profitability of Hester Biosciences Ltd saw substantial improvement in Q4FY26. The Profit Before Tax (PBT) for this quarter was ₹23.23 crores, marking a 90.3% increase from ₹12.21 crores in Q3FY26. Compared to the same quarter in the previous fiscal year, there was a remarkable year-over-year growth of 852.0%, as the PBT was only ₹2.44 crores in Q4FY25. Similarly, the Profit After Tax (PAT) in Q4FY26 was ₹16.54 crores, which is a 77.8% rise from ₹9.30 crores in Q3FY26 and a substantial increase of 974.0% from ₹1.54 crores in Q4FY25. This growth in profitability is also reflected in the Earnings Per Share (EPS), which increased by 77.8% quarter-over-quarter and 968.7% year-over-year, reaching ₹19.45 in Q4FY26.

Operating Metrics

The total expenses for Hester Biosciences Ltd in Q4FY26 amounted to ₹76.79 crores. When compared to the previous quarter's expenses of ₹65.87 crores, there was a 16.6% increase. On a year-over-year basis, total expenses grew by 5.9% from ₹72.54 crores in Q4FY25. The tax expenses also saw a significant rise, with a 102.9% increase from ₹4.21 crores in Q3FY26 to ₹8.54 crores in Q4FY26, and a 288.2% increase from ₹2.20 crores in Q4FY25. These changes in operating metrics highlight the company's cost management strategies and tax obligations within the reported period.